/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
-0.02%
Natural Gas
+0.58%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+1.03%
VIX
N/A
Economic Calendar
EUR/USD
-0.02%
Natural Gas
+0.58%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+1.03%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
RBA Governor Michele Bullock Pours Cold Water on Rate Hike Chatter
15 minutes ago
XRP Price Forecast: JPMorgan Cross-Border Payments Could Drive XRP to $1,000, Analyst says
2 days ago
Shiba Inu (SHIB) Overtakes BTC and DOGE as Most-Traded Coin in India
2 days ago
The Week Ahead: The RBA and the BoE in Focus Amidst Shifting Policy Outlooks
2 days ago
Five Things to Know in Crypto This Week: US Jobs Report Offers Relief
3 days ago
Shiba Inu Price Surges as PayPal announces SHIB Token Integration in USA
3 days ago
Natural Gas and Oil Forecast: Prices Recover; Will the Uptrend Continue Today?
about 1 hour ago
DAX Index Today: The German Economy and Corporate Earnings in the Spotlight
about 2 hours ago
Bitcoin (BTC) News Today: Tracking BTC Amid Fluctuating ETF Inflows and SEC Actions
about 3 hours ago
XRP News Today: Ripple and SEC Continue Battle, Investor Focus Sharpens
about 5 hours ago
USD/JPY Forecast: Services Data, Fed Talk to Drive Yen’s Price Action
about 7 hours ago
AUD to USD Forecast: Retail Sales and RBA Moves in the Spotlight
about 7 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
OMER
profile
Omeros Corporation
Follow
OMER
(
Nasdaq - US
)
N/A
3.67
-0.06 (-1.61%)
in
:
usd
•
As of: May 06, 2024 15:59
UTC -4
Open
3.79
High
3.79
Low
3.65
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Omeros Corporation
CEO
Gregory A. Demopulos
Headquarters
201 elliot avenue west
seattle, wa 98119, united states
Auditor
Ernst & Young LLP
Employees
198
Share Holders
84
Website
www.omeros.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Omeros Corporation
Statistics
Valuation Measures
Market Capitalization
2
212.64M
Enterprise Value
418.69M
Enterprise Value/EBITDA
(ttm)
-2.56
Price to Earnings Ratio
(ttm)
N/A
Price to Book
(mrq)
N/A
Price to Sales
(ttm)
N/A
Price to Cash
(ytd)
N/A
Profitability
Gross Margin
(ttm)
0.00%
Operating Margin
(ttm)
N/A
Profit Margin
(ttm)
0.00%
Return on Equity
(ttm)
-1916.35%
Return on Invested Capital
(ttm)
-78.40%
Return on Assets
(ttm)
-35.72%
Income Statement
Revenue
(ttm)
0.00
Revenue Per Share
(ttm)
0.00
Gross Profit
(ttm)
0.00
EBITDA
(ttm)
3
-163.61M
Net Income Avi to Common
(ttm)
-117.81M
Diluted EPS
(ttm)
-1.88
Share Statistics
Beta (5Y Monthly)
1.34
52-Week Change
-26.60%
S&P500 52-Week Change
27.73%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
57.94M
Dividend Yield
0.00%
Float
4
51.63M
%
Held by Insiders
10.90%
%
Held by Institutions
48.79%
Balance Sheet
Total Cash
(mrq)
171.85M
Total Cash Per Share
(mrq)
2.97
Total Debt
(mrq)
213.16M
Total Debt/Equity
(mrq)
-853.20%
Current Ratio
(mrq)
4.09%
Quick Ratio
(mrq)
4.09%
Book Value Per Share
(mrq)
-0.41
Cash Flow
Operating Cash Flow Per Share
(ytd)
1.19
Free Cash Flow
(ytd)
74.30M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker